The MIND-DC phase III clinical trial (NCT02993315) randomized 148 patients with melanoma in a 2:1 ratio to adjuvant treatment with nDC (pulsed with gp100, tyrosinase, NY-ESO-1, MAGE-C2 and MAGE-3 melanoma derived peptides, which are tumor associated antigens, TAA) versus placebo22 (Fig. 3A, Table S3). The gene discussed is MAGEC2; the disease is melanoma.